Acute ischemic stroke, particularly in patients without large- or medium-vessel occlusion, cardioembolic source, or adequate clinical response to intravenous tenecteplase, remains associated with uncertain treatment outcomes despite emerging adjunctive antiplatelet strategies. To address this gap, a study evaluated the efficacy and safety of intravenous tirofiban administered after an inadequate response to intravenous tenecteplase in 359 patients with acute ischemic stroke.
The study found that excellent 90-day outcomes were achieved in 63.8% of patients receiving tirofiban compared with 52.2% of patients receiving placebo, demonstrating a significantly greater likelihood of favorable recovery with tirofiban treatment. Symptomatic intracranial hemorrhage within 48 hours was rare, occurring in 0.9% of patients in the tirofiban group and in no patients in the placebo group, while 90-day…
